Figure 3.
Kaplan–Meier survival curves for 5-year (A) recurrence-free survival (RFS) and (B) overall survival (OS) for PORTEC-3 patients with HER2-positive and HER2-negative high-risk endometrial cancer (HREC); 5-year (C) RFS and (D) OS for patients with HER2-positive and HER2-negative p53 abnormal HREC.